Therefore, we assume that divalent peptide3A5 would provide anti-tumor activity with similar mechanism to Eritoran, which may improve the efficacy of anti-PD-1 antibody, and that multivalent S100A8 inhibitory peptides can be useful to improve the efficacy of other chemotherapeutic agents. This evidence concerns the gene S100A8 and neoplasm.